chrisvoncsefalvay/vaers-outcomes huggingface dataset:
15JUN97 530Pm broke out in hives mostly where clothes covered body;lips swollen & eyes puffy;pt took DPH w/some relief;had been working in hayfield all day stated had never had rxn to hay a/;16JUN97 seen in clinic;
At approximately 19 minutes after Vaccine administration the patient c/o feeling dizzy and nauseas.   V/S @  1600 hours :124/94, 104, O2 @ 96%.  Patient continued to decline with shivering,  shakey, and weakness.  Became sob, Sats dropped to 91%, HR 98. BP 84/52.  Lowered from chair to floor, given 50 mg of Benadryl IM. Although oxygen saturation level increased, urticaria, angioedema and hives noted to face,  4mg of Decadron and Epi administered.  Redness in face decreased, but lips and face still appeared large and tight  EMS was called and arrived @ approximately 16:12.  Transported to hospital @ 1624
I had cataract surgery a few years ago, and after that had successful YAG laser capsulotomy due to clouding of the "capsule" holding the artificial lens.  About 2 weeks post 2nd COVID shot, right eye vision deteriorated markedly with lots of blurring.  Had eye exam 3/11, diagnosed as needing YAG laser capsulotomy on Right eye for post-cateract capsular clouding -- successful.  By 3/31, left eye vision deteriorated markedly (blurred vision) and continued to deteriorate as determined by eye exams on 4/21 and today, 5/12.  Diagnosis is that I once again have a "membrane" clouding the capsule -- and I will have YAG surgery again. Normally YAG capsulotomy surgery does not have to be repeated. My eye doctor says a repeat of this condition is very rare and, when it happens, only in young people. The fact that these two events (right eye, then rare left eye capsular clouding issue in both cases needing YAG capsulotomy) happened beginning about  14 days or so post the second COVID shot was remarkable. I know that correlation does not equal causation, but my eye doctor also told me today that she has seen some other eye issues due to possible hyperactive immune responses stimulated by the COVID vaccine. Thus I am reporting this via VAERS just in case others might be reporting similar issues. My YAG surgery for the repeat left eye capsulotomy will be scheduled soon.
While sitting during the observation period, client states she began to have tingling on the right side of her tongue which lasted for 3-4min.  She did not say anything to staff at vaccination clinic.  Later in the evening she noticed her arm getting sore.  Upon waking up this AM ,  her harm was sore, swollen,  warm to touch.  States pain is about a 3 on pain scale of 1-10.  She also has an itchy rash on buttocks, which occurred the last time she had an allergic reaction to an arthritis medication.  When asked to describe the rash, she said she could not see it.  Denies fever.    Client advised to contact physician to notify of s/s.
The afternoon following the 2nd vaccine i broke out in hives and started itching. From the bottom of my feet to my neck. My legs, arms, back, stomach, hands. This went on for 4 days straight. It got worse in the evenings and at night; The afternoon following the 2nd vaccine i broke out in hives and started itching. From the bottom of my feet to my neck. My legs, arms, back, stomach, hands. This went on for 4 days straight. It got worse in the evenings and at night; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 12Apr2021 at 11:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included cardiomyopathy, congestive heart failure and left bundle branch block. The patient had known allergies to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified concomitant medications; taken for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 22Mar2021 at 11:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient previously received iodine (MANUFACTURER UNKNOWN) and experienced drug allergy. On 12Apr2021 at 15:00, the afternoon following the second vaccine, the patient experienced break out in hives and started itching. From the bottom of her feet to neck. Her legs, arms, back, stomach, hands. This went on for 4 days straight. It got worse in the evenings and at night. It slacked off for a few days and started back up. It was so unbearable that she had to go to the emergency room. The events resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with 3 different medications which were unspecified. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events the afternoon following the second vaccine the patient had break out in hives and started itching from the bottom of her feet to her neck, legs, arms, back, stomach, hands, this went on for 4 days straight and it got worse in the evenings and at night was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Lumbar stiffness and pain, sore knees joints, arthritis-like pain in joints below waist and arms, fingers.
Felt feverish symptoms that woke me up from sleep at 2:30 am. Alternation between body chills and sweats. Joint and muscle pain all over my body. Symptoms were resolved for several hours after taking two Advil tablets at about 4:30 am. At about 11:30 am, the bodyaches returned, and were again resolved by taking three ibuprofen tablets at about 12:30 pm. The symptoms did not return.
A report has been received from a health professional concerning a female patient. Medical history and concomitant medications of the patient was not reported. The patient had received FLUMIST (intranasal) on 05-Nov-2013. It was reported that the patient was tested positive for Flu A. Patient was not hospitalized and was treated with TAMIFLU. Action taken with FLUMIST was not applicable. The outcome of the event of flu was unknown. The reporter considered the event Flu A to be non-serious.
patient presented for an anticoag visit on 9/29/21 with me at Market & asked for his Covid booster, as he is a COPD & PE patient & he told me he had received a Pfizer vaccine at the end of June /21, (didn?t present a vaccine card & no detail was in medical record at the time of appt, I proceeded to give him a Pfizer Booster). Later after the MA researched what he actually had as first vaccine ( JJ) I was notified of the error & called CDC for recommendations to Provider & report for vax error. No adverse reaction was reported By patient or caregiver. I assumed wherever he had gotten the 1st Vaccine, would not have given an anti coag patient the JJ due to clot risk. Spoke to Patient caregiver 10/12/21  & patient is having no untoward effects post Vaccine at all. WAS DIRECTED TO SUBMIT A VAERS DESPITE ANY ADVERSE REACTION TO DOSE FOR TRACKING RECORDS & PER OUR LEGAL DEPARTMENT
The caller states it looks like a similar reaction the caller had to the second dose Pneumonia vaccine, where arm became swollen; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70 year-old female patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13) (Batch/Lot number: unknown) as dose 2, single for immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Pneumococcal vaccine (dose 1, manufacture unknown), for immunization. The following information was reported: PERIPHERAL SWELLING (non-serious), outcome "unknown", described as "The caller states it looks like a similar reaction the caller had to the second dose Pneumonia vaccine, where arm became swollen". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
doses administered past the published expiry date; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (doses administered past the published expiry date) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (doses administered past the published expiry date). On 12-Oct-2021, EXPIRED PRODUCT ADMINISTERED (doses administered past the published expiry date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No Treatment informations were reported.
Severe abdominal pain, severe shoulder pain (both shoulders), severe neck pain. Pain did not respond to OTC pain relievers or heat therapies.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. Patient medical history and current condition was not reported. On 08-APR-2015 the patient was vaccinated with RECOMBIVAX HB injection of strength 5/0.5 microgram/ml (lot # K014548 and expiry date 27-AUG-2016) and PEDIARIX. No adverse symptoms reported. Product quality complaint was not reported. The outcome of the events was unknown. This case is one of the two reports and linked via sibling link (1505USA003005). Additional information has been requested.
Information has been received from a registered nurse, concerning a patient of an unknown age and gender. The patient's medical history, drug allergies, previously drug reactions, concurrent conditions and concomitant medication were not reported. On 29-SEP-2017, the patient was vaccinated with one unspecified expired dose of ZOSTAVAX strength: 19400 PFU subcutaneously, lot number: M014310 with expiration date of 26-MAY-2017 (dose number and anatomical location were not provided) for prophylaxis, reconstituted with sterile diluent (MRK) (lot number and expiration date were unknown). No adverse effects were reported.
Immediate histamine reaction after shot (post nasal drip, sore throat, feeling of lump in throat). Immediate soreness in arm at injection site. Symptoms lasted 3 days. Rash and itching at injection site 2.5 weeks after vaccine. Symptoms lasted 3 days
Narrative: Patient with breakthrough covid infection. Tested positive 8/31/21. 2 doses of moderna vaccine received outside of facility
No additional AE reported; Patient was accidently administered PROQUAD via intramuscular route.; This spontaneous report was received from a medical assistant concerning a 6-year-old male patient.  The patient's pertinent medical history, other drug reactions and allergies, concurrent conditions and concomitant therapies were not reported.  On 19-OCT-2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, lot number W012741has been determined to be valid for measles, mumps, rubella and varicella (oka-merck), expiration date reported and established as 16-OCT-2023, via intramuscular (incorrect route of product administration) as prophylaxis (strength not provided). No additional adverse events were reported.   At the time of reporting, the outcome of the events was not provided.
This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions, drug reactions, allergies or concomitant medications. On 25-JUL-2018, the patient was vaccinated with an improperly stored dose of VARIVAX for prophylaxis (strength, dose number, anatomical location, route of administration were not reported). There was unknown if the patient received the lot No N031001 (Exp date 03-NOV-2019), lot No N034557 (Exp date 05-DEC-2019) or lot No N034553 (Exp date 05-DEC-2019). The VARIVAX was reconstituted with a properly stored sterile diluent and there was not adverse effect reported. The temperature was from 6 degrees Fahrenheit (°F) to 14°F for a time frame of 35 minutes without previous temperature excursions and was called because a digital data logger. This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1807USA011606: US-009507513-1807USA012253: US-009507513-1807USA012256: US-009507513-1807USA012264: US-009507513-1807USA012258: US-009507513-1807USA012259: US-009507513-1807USA012260: US-009507513-1807USA012262: US-009507513-1807USA012263: US-009507513-1807USA012255: US-009507513-1807USA012254: US-009507513-1807USA012257:
Tdap 4/28.  Left arm pain/swelling 4/29 - up to shoulder, neck, 5 cm mass-like swelling - tender, hurts to move.
Impaired hearing started on 3/8/2021 in left ear only.  Ringing in ear all day on 3/11/2021.  Loss of hearing progressed each day in left ear.  Had doctor appointment on 3/15/2021.  Per Doctor, PCP,  both ears look clear.  Gave referral to see a specialist to check middle ear.
Huge injection site reaction; She has felt horrible/felt awful; Pharmacy administered the shot subcutaneously in the back of the left arm; Vaccine administered at inappropriate site; Fever of 103 degrees; Muscle Aches; Headache; This case was reported by a nurse via call center representative and described the occurrence of headache in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of pyrexia (1st dose received on 26th October 2019 and experienced fever, please refer case US2019AMR196003).   On 26th October 2019, the patient received the 2nd dose of Shingrix (subcutaneous). In October 2019, less than a week after receiving Shingrix, the patient experienced headache and muscle pain. On 26th October 2019, the patient experienced fever, injection site reaction, feels awful, wrong route of administration and vaccine administered at inappropriate site. On 28th October 2019, the outcome of the fever was recovered/resolved. On an unknown date, the outcome of the headache and injection site reaction were not recovered/not resolved and the outcome of the muscle pain was recovered/resolved and the outcome of the feels awful, wrong route of administration and vaccine administered at inappropriate site were unknown.   It was unknown if the reporter considered the headache, fever, muscle pain, injection site reaction and feels awful to be related to Shingrix.  Additional details were received as follows: The patient was been administered by Shingrix subcutaneously in the back of the left arm instead of intramuscularly in the deltoid, which led to wrong route of administration and vaccine administered at inappropriate site. She states that the back of her arm there was a huge injection site reaction. She states that with this injection she has felt horrible.  Later in the same day of vaccination, the patent experienced a fever of 103 degrees and felt awful.  She also experienced muscle aches and a bad headache. She said the headache was so terrible she couldn't get her head off the pillow.  On 28th October 2019, fever has stopped and the muscle aches have gone away but she still has a slight headache. She says the headache was much more vague at the time of reporting. She did not have the lot/exp of the injection. This case was linked with case US2019AMR196003, reported by the same reporter.
PATIENT UNDER AGE 18 WAS GIVEN JANSSEN COVID-19 VACCINE.
no adverse effect; multiple patients were vaccinated with improperly stored VAQTA on multiple dates; This spontaneous report was received from a medical assistant refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 15-APR-2019, the patient was vaccinated with improperly stored hepatitis a vaccine, inactivated(VAQTA) lot # R027431, expiry date 08-SEP-2019 for prophylaxis.  No adverse event was reported. Previous temperature excursion was reported. Data logger was involved.
Both my wife and I began experiencing Dyshidrotic eczema after receiving the vaccine. Mine is limited to the tip of my pinky finger of my right hand. My wife is experiencing it on both palms. This condition cannot be cured but only treated
Flu like symptoms second and third day. Low grade fever, chills, headache, light nausea, fatigue.
Information has been received from a registered nurse concerning a 67 year old female who on 19-SEP-2007 was vaccinated with ZOSTAVAX (Oka/Merck) (lot#: 658085/0882U) subcutaneously. Subsequently the patient developed Shingles. The shingles are located on her upper arm, shoulder and her breast. The lesions were draining "last week" (beginning of July, 2008) and were starting to scab. On 03-JUL-2008, the patient was placed on antivirals. The patient sought unspecified medical attention and was seen by a dermatologist. A sample of the herpes zoster was not obtained since there was "nothing to send". The patient's final outcome was not known. Additional information has been requested.
Discomfort, redness and swelling in upper arm. Treated with ice and elevation. Seen by physician.
Information has been received from a RN concerning a pt who on 01/25/1996 was vaccinated with a dose of varicella virus vaccine live.  Subsequently, on 03/07/1997 the pt developed chicken pox. It was noted that the mother had chicken pox also. The pt was seen  in the office. The reporter also indicated that 30 other pt's were vaccianted. with varicella virus vaccine live and developed chickenpox. (WAES 0409USA01045, 0409USA01046, 0409USA01047, 0409USA01048, 0409USA01049, 0409USA01050, 0409USA01051, 0409USA01052, 0409USA01053, 0409USA01054, 0409USA01055, 0409USA01056, 0409USA01057, 0409USA01058, 0409USA01059, 0409USA01060, 0409USA01061, 0409USA01062, 0409USA01063, 0409USA01064, 0409USA01065, 0409USA01066, 0409USA01067, 0409USA01068, 0409USA01069, 0409USA01070, 0409USA01071, 0409USA01072, 0409USA01073, AND 0409USA01074. No further infomration is expected.
exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a patient and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (exposure during pregnancy) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     The patient's past medical history included Alcohol use (2-3 drinks per week) in August 2020. Concurrent medical conditions included Asthma since 1992. Concomitant products included FLUTICASONE PROPIONATE (FLONASE ALLERGY RELIEF) for Allergy, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR) for Asthma, PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for Pregnancy.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 09-Jul-2020 and the estimated date of delivery was 15-Apr-2021. On 14-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-seventh week of the pregnancy.  On 14-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (exposure during pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Sep-2020, Ultrasound scan: normal (normal) normal. On 11-Nov-2020, Ultrasound scan: normal (normal) normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient had previous 2 pregnancies. First pregnancy was full term birth on 22-Nov-2015 and second pregnancy was full term birth as well on 26-Jul-2018.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this 31-year-old female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
This spontaneous case was reported by a consumer and describes the occurrence of DIVERTICULITIS (worsening of diverticulitis) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Concurrent medical conditions included Diverticulitis (10 years ago). On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced DIVERTICULITIS (worsening of diverticulitis) (seriousness criterion medically significant). At the time of the report, DIVERTICULITIS (worsening of diverticulitis) outcome was unknown. No concomitant drug was reported. Treatment medication was reported as 10 day course of antibiotics to treat diverticulitis. Company comment: This is a spontaneous case concerning a female patient of an unknown age with concurrent medical condition of diverticulitis who received 3 doses of mRNA-1273 vaccine and experienced serious (medically significant), unexpected event of worsening of diverticulitis. Vaccination date and onset date of the event were not provided; hence, latency cannot be assessed. The patient stated that she was diagnosed with diverticulitis 10 years ago, but this was the first time she ever had to take an antibiotic to treat her diverticulitis. She wanted to know if it was okay to get the second booster dose since she was taking an antibiotic. No further details regarding clinical course or diagnostic tests were disclosed. Concurrent medical condition of diverticulitis remains a contributory factor. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Reporter did not allow further contact. Sender's Comments: This is a spontaneous case concerning a female patient of an unknown age with concurrent medical condition of diverticulitis who received 3 doses of mRNA-1273 vaccine and experienced serious (medically significant), unexpected event of worsening of diverticulitis. Vaccination date and onset date of the event were not provided; hence, latency cannot be assessed. The patient stated that she was diagnosed with diverticulitis 10 years ago, but this was the first time she ever had to take an antibiotic to treat her diverticulitis. She wanted to know if it was okay to get the second booster dose since she was taking an antibiotic. No further details regarding clinical course or diagnostic tests were disclosed. Concurrent medical condition of diverticulitis remains a contributory factor. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.